Plasma levels of the arterial wall protein fibulin-1 are associated with carotid-femoral pulse wave velocity: A cross-sectional study

Cardiovascular Diabetology

Volumn 12, Issue 1, 2013, Pages

  Laugesen, Esben ^a   Høyem, Pernille ^a   Christiansen, Jens Sandahl ^a   Knudsen, Søren Tang ^a   Hansen, Klavs Würgler ^b   Argraves, W Scott ^c   Hansen, Troels Krarup ^a   Poulsen, Per Løgstrup ^a   Rasmussen, Lars Melholt ^d  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b SILKEBORG REGIONAL HOSPITAL   (Denmark)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^d UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

Arterial stiffness; Fibulin 1; Pulse wave velocity; Type 2 diabetes mellitus

Indexed keywords

FIBULIN; FIBULIN 1; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; CALCIUM BINDING PROTEIN;

ADULT; ARTERIAL STIFFNESS; ARTERY WALL; ARTICLE; CAROTID ARTERY PULSE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; EXTRACELLULAR MATRIX; FEMALE; FEMORAL ARTERY FLOW; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN BLOOD LEVEL; PULSE PRESSURE; PULSE WAVE; AGED; BLOOD; CAROTID ARTERY; CASE CONTROL STUDY; COMPLICATION; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; FEMORAL ARTERY; IMMUNOASSAY; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOPHYSIOLOGY; PREDICTIVE VALUE; RISK FACTOR;

AGED; BIOLOGICAL MARKERS; CALCIUM-BINDING PROTEINS; CAROTID ARTERIES; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; FEMORAL ARTERY; HUMANS; IMMUNOASSAY; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; PULSE WAVE ANALYSIS; RISK FACTORS; VASCULAR STIFFNESS;

EID: 84880183610     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-12-107     Document Type: Article

References (36)

1. Seshasai SR, Kaptoge S, Thompson A, Di AE, Gao P, Sarwar N, Whincup PH, Mukamal KJ, Gillum RF, Holme I, et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med 2011, 364:829-841.
2. Schramm TK, Gislason GH, Kober L, Rasmussen S, Rasmussen JN, Abildstrom SZ, Hansen ML, Folke F, Buch P, Madsen M, et al. Diabetes patients requiring glucose-lowering therapy and nondiabetics with a prior myocardial infarction carry the same cardiovascular risk: a population study of 3.3 million people. Circulation 2008, 117:1945-1954. 10.1161/CIRCULATIONAHA.107.720847, 18378618.
3. Laurent S, Cockcroft J, Van BL, Boutouyrie P, Giannattasio C, Hayoz D, Pannier B, Vlachopoulos C, Wilkinson I, Struijker-Boudier H. Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J 2006, 27:2588-2605. 10.1093/eurheartj/ehl254, 17000623.
4. Stehouwer CD, Henry RM, Ferreira I. Arterial stiffness in diabetes and the metabolic syndrome: a pathway to cardiovascular disease. Diabetologia 2008, 51:527-539. 10.1007/s00125-007-0918-3, 18239908.
5. Sims TJ, Rasmussen LM, Oxlund H, Bailey AJ. The role of glycation cross-links in diabetic vascular stiffening. Diabetologia 1996, 39:946-951. 10.1007/BF00403914, 8858217.
6. Rasmussen LM, Heickendorff L. Accumulation of fibronectin in aortas from diabetic patients. A quantitative immunohistochemical and biochemical study. Lab Invest 1989, 61:440-446.
7. Heickendorff L, Ledet T, Rasmussen LM. Glycosaminoglycans in the human aorta in diabetes mellitus: a study of tunica media from areas with and without atherosclerotic plaque. Diabetologia 1994, 37:286-292. 10.1007/BF00398056, 8174843.
8. Rasmussen LM, Ledet T. Aortic collagen alterations in human diabetes mellitus. Changes in basement membrane collagen content and in the susceptibility of total collagen to cyanogen bromide solubilisation. Diabetologia 1993, 36:445-453. 10.1007/BF00402282, 8314450.
9. Tanno T, Yoshinaga K, Sato T. Alteration of elastin in aorta from diabetics. Atherosclerosis 1993, 101:129-134. 10.1016/0021-9150(93)90109-8, 8379957.
10. Chung AW, Booth AD, Rose C, Thompson CR, Levin A, van BC. Increased matrix metalloproteinase 2 activity in the human internal mammary artery is associated with ageing, hypertension, diabetes and kidney dysfunction. J Vasc Res 2008, 45:357-362. 10.1159/000119755, 18332634.
11. Cangemi C, Skov V, Poulsen MK, Funder J, Twal WO, Gall MA, Hjortdal V, Jespersen ML, Kruse TA, Aagard J, et al. Fibulin-1 is a marker for arterial extracellular matrix alterations in type 2 diabetes. Clin Chem 2011, 57:1556-1565. 10.1373/clinchem.2011.162966, 21926180.
12. Laurent S, Boutouyrie P, Asmar R, Gautier I, Laloux B, Guize L, Ducimetiere P, Benetos A. Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertension 2001, 37:1236-1241. 10.1161/01.HYP.37.5.1236, 11358934.
13. Boutouyrie P, Tropeano AI, Asmar R, Gautier I, Benetos A, Lacolley P, Laurent S. Aortic stiffness is an independent predictor of primary coronary events in hypertensive patients: a longitudinal study. Hypertension 2002, 39:10-15. 10.1161/hy0102.099031, 11799071.
14. Sutton-Tyrrell K, Najjar SS, Boudreau RM, Venkitachalam L, Kupelian V, Simonsick EM, Havlik R, Lakatta EG, Spurgeon H, Kritchevsky S, et al. Elevated aortic pulse wave velocity, a marker of arterial stiffness, predicts cardiovascular events in well-functioning older adults. Circulation 2005, 111:3384-3390. 10.1161/CIRCULATIONAHA.104.483628, 15967850.
15. Blacher J, Guerin AP, Pannier B, Marchais SJ, Safar ME, London GM. Impact of aortic stiffness on survival in end-stage renal disease. Circulation 1999, 99:2434-2439. 10.1161/01.CIR.99.18.2434, 10318666.
16. Willum-Hansen T, Staessen JA, Torp-Pedersen C, Rasmussen S, Thijs L, Ibsen H, Jeppesen J. Prognostic value of aortic pulse wave velocity as index of arterial stiffness in the general population. Circulation 2006, 113:664-670. 10.1161/CIRCULATIONAHA.105.579342, 16461839.
17. Mitchell GF, Hwang SJ, Vasan RS, Larson MG, Pencina MJ, Hamburg NM, Vita JA, Levy D, Benjamin EJ. Arterial stiffness and cardiovascular events: the Framingham heart study. Circulation 2010, 121:505-511. 10.1161/CIRCULATIONAHA.109.886655, 2836717, 20083680.
18. Maldonado J, Pereira T, Polonia J, Silva JA, Morais J, Marques M. Arterial stiffness predicts cardiovascular outcome in a low-to-moderate cardiovascular risk population: the EDIVA (Estudo de DIstensibilidade VAscular) project. J Hypertens 2011, 29:669-675. 10.1097/HJH.0b013e3283432063, 21252699.
19. Cruickshank K, Riste L, Anderson SG, Wright JS, Dunn G, Gosling RG. Aortic pulse-wave velocity and its relationship to mortality in diabetes and glucose intolerance: an integrated index of vascular function?. Circulation 2002, 106:2085-2090. 10.1161/01.CIR.0000033824.02722.F7, 12379578.
20. World Health Organization Consultation Group Definition, Diagnosis, and Classification of Diabetes Mellitus and its Complications 1999, 1-59. Geneva, Switzerland: World Health Organization, 2, Part 1: Diagnosis and classification of diabetes mellitus, World Health Organization Consultation Group.
21. Argraves WS, Tran H, Burgess WH, Dickerson K. Fibulin is an extracellular matrix and plasma glycoprotein with repeated domain structure. J Cell Biol 1990, 111:3155-3164. 10.1083/jcb.111.6.3155, 2116371, 2269669.
22. Chiu YC, Arand PW, Shroff SG, Feldman T, Carroll JD. Determination of pulse-wave velocities with computerized algorithms. Am Heart J 1991, 121:1460-1470. 10.1016/0002-8703(91)90153-9, 2017978.
23. Kruger R, Schutte R, Huisman HW, Argraves WS, Rasmussen LM, Olsen MH, Schutte AE. NT-proBNP is associated with fibulin-1 in Africans: The SAfrEIC study. Atherosclerosis 2012, 222:216-221. 10.1016/j.atherosclerosis.2012.01.045, 22349089.
24. Shargorodsky M, Omelchenko E, Matas Z, Boaz M, Gavish D. Relation between augmentation index and adiponectin during one-year metformin treatment for nonalcoholic steatohepatosis: effects beyond glucose lowering?. Cardiovasc Diabetol 2012, 11:61. 10.1186/1475-2840-11-61, 3471007, 22676459.
25. Sofer E, Boaz M, Matas Z, Mashavi M, Shargorodsky M. Treatment with insulin sensitizer metformin improves arterial properties, metabolic parameters, and liver function in patients with nonalcoholic fatty liver disease: a randomized, placebo-controlled trial. Metabolism 2011, 60:1278-1284. 10.1016/j.metabol.2011.01.011, 21411114.
26. Agarwal N, Rice SP, Bolusani H, Luzio SD, Dunseath G, Ludgate M, Rees DA. Metformin reduces arterial stiffness and improves endothelial function in young women with polycystic ovary syndrome: a randomized, placebo-controlled, crossover trial. J Clin Endocrinol Metab 2010, 95:722-730. 10.1210/jc.2009-1985, 19996308.
27. Meyer C, McGrath BP, Teede HJ. Effects of medical therapy on insulin resistance and the cardiovascular system in polycystic ovary syndrome. Diabetes Care 2007, 30:471-478. 10.2337/dc06-0618, 17327307.
28. Scholze A, Bladbjerg EM, Sidelmann JJ, Diederichsen AC, Mickley H, Nybo M, Argraves WS, Marckmann P, Rasmussen LM. Plasma concentrations of extracellular matrix protein fibulin-1 are related to cardiovascular risk markers in chronic kidney disease and diabetes. Cardiovasc Diabetol 2013, 12:6. 10.1186/1475-2840-12-6, 3570481, 23294625.
29. Reference Values for Arterial Stiffness' Collaboration Determinants of pulse wave velocity in healthy people and in the presence of cardiovascular risk factors: 'establishing normal and reference values'. Eur Heart J 2010, 31:2338-2350. 2948201, 20530030, Reference Values for Arterial Stiffness' Collaboration.
30. Woolam GL, Schnur PL, Vallbona C, Hoff HE. The pulse wave velocity as an early indicator of atherosclerosis in diabetic subjects. Circulation 1962, 25:533-539. 10.1161/01.CIR.25.3.533, 14008268.
31. Roark EF, Keene DR, Haudenschild CC, Godyna S, Little CD, Argraves WS. The association of human fibulin-1 with elastic fibers: an immunohistological, ultrastructural, and RNA study. J Histochem Cytochem 1995, 43:401-411. 10.1177/43.4.7534784, 7534784.
32. Balbona K, Tran H, Godyna S, Ingham KC, Strickland DK, Argraves WS. Fibulin binds to itself and to the carboxyl-terminal heparin-binding region of fibronectin. J Biol Chem 1992, 267:20120-20125.
33. Aspberg A, Adam S, Kostka G, Timpl R, Heinegard D. Fibulin-1 is a ligand for the C-type lectin domains of aggrecan and versican. J Biol Chem 1999, 274:20444-20449. 10.1074/jbc.274.29.20444, 10400671.
34. Lawlor DA, Harbord RM, Sterne JAC, Timpson N, Smith GD. Mendelian randomization: using genes as instruments for making causal inferences in epidemiology. Stat Med 2008, 27:1133-1163. 10.1002/sim.3034, 17886233.
35. Burgess S, Butterworth A, Malarstig A, Thompson SG. Use of Mendelian randomisation to assess potential benefit of clinical intervention. Br Med J 2012, 345:e7325.
36. Vallve JC, Serra N, Zalba G, Fortuno A, Beloqui O, Ferre R, Ribalta J, Masana L. Two variants in the fibulin2 gene are associated with lower systolic blood pressure and decreased risk of hypertension. PLoS One 2012, 7:e43051. 10.1371/journal.pone.0043051, 3418224, 22912785.